View Archive

2nd Annual Paris Breast Cancer Conference™

2nd Annual Paris Breast Cancer Conference™

16-17 November, 2018
Paris, France

The Westin Paris-Vendôme
3 Rue de Castiglione
Paris, 75001, France
Tel: +33 (0) 1 44 77 11 11




click to View Brochure and Agenda

New agents, emerging strategies, and optimization of established regimens are changing the delivery of breast cancer therapy. Over the past decade, tremendous progress in the treatment of breast cancers has led to improved outcomes for patients, but has also complicated clinical management in this setting. We are excited to announce the 2nd Annual Paris Breast Cancer Conference™, a comprehensive educational conference designed to help practitioners place emerging information into the context of landmark clinical trial data and established standards of care, with the goal of ultimately improving the care they provide to their patients with breast cancers.

This practical and interactive multiday program features a faculty of leading international experts who will provide up-to-date information and guidance via didactic lectures, question-and-answer sessions, and extended interactive, case-based panel discussions. This format will enable participants to engage the faculty in a direct exchange of perspectives, personal experiences, and strategies related to clinical challenges in the management of breast cancers.

This meeting is not to be missed! The activity will to continue the legacy and tradition of Physicians’ Education Resource®, LLC, in providing clinicians with the knowledge and confidence to maintain state-of-the-art care and to optimize outcomes for patients with cancer.

Can't-Miss Topics

  • Perspectives on emerging strategies
    • Immunotherapeutics for early-stage, triple-negative breast cancer (TNBC)
    • Antibody-drug conjugates in metastatic TNBC
    • Molecular testing for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer
    • Targeted therapies for HER2-positive metastatic breast cancer
    • Robot-assisted surgery
    • Short preoperative systemic therapy for early luminal breast cancer
    • Genomics for hormone-receptor (HR)‒positive, metastatic breast cancer
  • Patient selection for carboplatin in early TNBC
  • How to treat residual TNBC after neoadjuvant chemotherapy
  • Germline alteration testing in TNBC
  • Clinical updates on targeted therapies including T-DM1, PI3K inhibitors, PARP inhibitors, CDK4/6 inhibition, and HER2-targeted agents
  • Management of brain metastases
  • Treatment de-escalation for small HER2-positive tumors
  • Updates in locoregional therapies
  • Practical guidance on individualizing and optimizing therapy, including endocrine and anthracycline-free regimens
  • Challenging case debates
  • And more!

Benefits of Attending

  • Incorporate the latest data on targeted therapies into practice
  • Challenge the experts with your most difficult cases
  • Learn new frontiers for metastatic and triple-negative disease
  • Connect with top minds in the management of breast cancer
  • Learn updates to guidelines, management, and personalized care

Target Audience

This educational activity is directed toward health care professionals who practice primarily outside of the United States. It is specifically designed for medical oncologists and other health care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc) involved in the treatment and management of patients with breast cancer.

Educational Objectives:

At the conclusion of this activity, participants should be better prepared to:

  • Individualize treatment planning for patients with breast cancer based on the appropriate use and interpretation of biomarker results and molecular or genomic assays
  • Delineate local treatment approaches, such as surgery and radiation therapy, as well as systemic preoperative therapies, to manage patients with early-stage or locally advanced breast cancer
  • Integrate recent clinical trial evidence into personalized treatment strategies for the management of patients with breast cancer
  • Discuss emerging data regarding investigational approaches for managing breast cancer in the context of evolving treatment paradigms
  • Discuss methods to facilitate awareness of clinical trials among patients who may benefit from inclusion in studies evaluating investigation

Program Chair

Fabrice André, MD, PhD
Professor in the Department of Medical Oncology,
Institut Gustave Roussy,
Villejuif, France

Nicholas Turner, MD, PhD
Academic Consultant Medical Oncologist Biomedical Research Centre
The Royal Marsden NHS Foundation Trust
The Institute of Cancer Research
London, United Kingdom


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By